These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162 [TBL] [Abstract][Full Text] [Related]
12. Recanalized Thrombus Treated With a Paclitaxel-Coated Balloon: Insights from Optical Coherence Tomography. Watanabe Y; Fujino Y; Ishiguro H; Nakamura S JACC Cardiovasc Interv; 2016 Mar; 9(6):618-20. PubMed ID: 27013163 [No Abstract] [Full Text] [Related]
14. Imaging Comparison of a Bioresorbable Vascular Scaffold by High-Frequency Intravascular Ultrasound and Optical Coherence Tomography. Shan P; Motivala A; Moses J; Maehara A; Mintz GS; Ali ZA JACC Cardiovasc Interv; 2015 Sep; 8(11):e187-e188. PubMed ID: 26404210 [No Abstract] [Full Text] [Related]
15. Serial assessment of bioresorbable-polymer sirolimus-eluting stent by coronary angioscopy and optical coherence tomography. Nakamura S; Kimura S; Nakagama S; Hayashi Y; Yamamoto T; Utsugi Y; Doi J; Mizusawa M; Araki M; Sudo Y; Hishikari K; Hikita H; Takahashi A; Isobe M Coron Artery Dis; 2017 Sep; 28(6):530-531. PubMed ID: 28402989 [No Abstract] [Full Text] [Related]
16. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Wiebe J; Möllmann H; Most A; Dörr O; Weipert K; Rixe J; Liebetrau C; Elsässer A; Achenbach S; Hamm C; Nef H Clin Res Cardiol; 2014 Feb; 103(2):141-8. PubMed ID: 24136291 [TBL] [Abstract][Full Text] [Related]
17. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
18. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042 [TBL] [Abstract][Full Text] [Related]